Press release content from Globe Newswire. The AP news staff was not involved in its creation.

HTG Announces One-for-Twelve Reverse Stock Split

PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
December 20, 2022 GMT

TUCSON, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced that as a result of its one-for-twelve reserve stock split which became effective at 4:15 p.m. Eastern Time on December 20, 2022, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) effective with the open of the market tomorrow, Wednesday, December 21, 2022. HTG’s common stock will continue to trade under the ticker symbol “HTGM.”

As a result of the reverse stock split, each twelve pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.

Stockholders of record will receive information regarding their share ownership from HTG’s transfer agent, American Stock Transfer & Trust Company, LLC. (“AST”). AST can be reached at (877) 248-6417 or (718) 921-8337.

For additional information regarding the reverse stock split, please refer to HTG’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 20, 2022.

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit

Investor Contact:

Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577